NewsBenzingaBridgeBio präsentiert neue Phase-3-Analysen der ATTRibute-CM-Studie und Real-World-Evidenz für Acoramidis bei Transthyretin-Amyloid-Kardiomyopathie auf den AHA Scientific Sessions 2026 und der XX ISA 2026 BridgeBio präsentiert neue Phase-3-Analysen der ATTRibute-CM-Studie und Real-World-Evidenz für Acoramidis bei Transthyretin-Amyloid-Kardiomyopathie auf den AHA Scientific Sessions 2026 und der XX ISA 2026 Benzinga 2026.11.17 12:38 (GMT+0) Open on Benzinga Other news Why Microsoft Thinks Smaller, Cheaper AI Can Beat Claude and GPT Here’s How Much You Would Have Made Owning Royal Caribbean Group Stock In The Last 15 Years Nvidia says its open-source AI strategy remains intact after Jensen Huang’s exit $1000 Invested In Teck Resources 5 Years Ago Would Be Worth This Much Today 'Microsoft Executive Says Nvidia Drama Could Boost Rival Chips'- Bloomberg Nvidia says it doesn’t plan to reappoint Jensen Huang as CEO